VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer

摘要: Thirty-seven extensive disease SCLC patients were treated with ifosfamide 1.0 g/m2 (maximum 1.75 g), VP-16 (etoposide) 75 mg/m2 and cisplatin 20 (VIP) daily for 5 days in hospital. Mesna was given as a continuous infusion until 12 h after the last dose. Treatment reduced to 4 first 8 experienced serious myelotoxicity. 30 evaluable response. (27%) achieved complete response 60% had partial The median duration of 23 weeks. survival all 37 41 weeks, 47 weeks patients. Fifty per cent 26% treatment courses associated grade 3 granulocytopenia, respectively. There eight febrile events including four treatment-related deaths from sepsis on 5-day regimen. Although VIP generally rapid, proportion achieving (27% patients) is similar standard chemotherapy regimens which are less toxic complex administer.